Purpose: The aim of this study was to test a novel dual-modality imaging system that combines full-field digital mammography (FFDM) and automated breast ultrasound (ABUS) in a single platform. Our Aceso system, named after the Greek goddess of healing, was specifically designed for the early detection of cancer in women with dense breast tissue.
Materials And Methods: Aceso was first tested using two industry standards: a Contrast Detail Mammography (CDMAM) phantom as endorsed by European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services was used to assess the FFDM images; and the CIRS 040GSE ultrasound phantom was imaged to evaluate the quality of the ABUS images. In addition, 58 women participated in a clinical trial: 51 were healthy volunteers aged between 40 and 65, while 7 were patients referred by the breast clinic, 6 of whom had biopsy-proven breast cancer.
Results: The CDMAM tests showed that the FFDM results were "acceptable" but fell short of "achievable" which was attributed to the low dose used. The ABUS images had good depth penetration (80 mm) and adequate axial resolution (0.5 mm), but the lateral resolution of 2 mm was judged to be too coarse. In a 42-year-old volunteer with extremely dense breast tissue, the ABUS modality detected a lesion (a benign cyst) that was mammographically occult in the FFDM image. For a 73-year-old patient with fatty breasts, a malignant lesion was successfully detected and co-registered in the FFDM and ABUS images. On average, each woman spent less than 11 min in the acquisition room.
Conclusions: While there is room for improvement in the quality of both the FFDM and ABUS images, Aceso has demonstrated its ability to acquire clinically meaningful images for a range of women with varying breast densities and, therefore, has potential as a screening device.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4853655 | PMC |
http://dx.doi.org/10.1016/j.clinimag.2015.11.024 | DOI Listing |
Cancer Causes Control
January 2025
North Valley Breast Clinic, 1335 Buenaventura Blvd, Suite 204, Redding, CA, 96001, USA.
Objectives: Automated breast ultrasound imaging (ABUS) results in a reduction in breast cancer stage at diagnosis beyond that seen with mammographic screening in women with increased breast density or who are at a high risk of breast cancer. It is unknown if the addition of ABUS to mammography or ABUS imaging alone, in this population, is a cost-effective screening strategy.
Methods: A discrete event simulation (Monte Carlo) model was developed to assess the costs of screening, diagnostic evaluation, biopsy, and breast cancer treatment.
Zhonghua Zhong Liu Za Zhi
November 2024
Department of Ultrasound, Xijing Hospital, the First Affiliated Hospital of Air Force Medical University, Xi'an710032, China.
To construct a remote screening network for breast cancer based on automated breast ultrasound (ABUS) and explore the value of ABUS with remote reading for breast cancer screening. We constructed a remote breast cancer screening network including one remote reading center and 48 image-acquisition centers. We recruited women to participate in breast cancer screening at one of these image-acquisition centers from January 2021 to January 2023.
View Article and Find Full Text PDFAJR Am J Roentgenol
October 2024
Department of Ultrasound, Xijing Hospital, Fourth Military Medical University, No. 127 Changle West Road, Xi'an 710032, China.
China has faced barriers to implementation of a population-based mammographic screening program. Breast ultrasound provides an alternative screening modality to mammography in low-resource settings. To evaluate the performance of ABUS with remote reading as the primary screening modality for breast cancer.
View Article and Find Full Text PDFJ Pers Med
August 2024
DIM-Interdisciplinary Department of Medicine, Section of Diagnostic Imaging and Radiation Oncology, Aldo Moro University of Bari Medical School, Piazza Giulio Cesare 11, 70124 Bari, Italy.
Neoadjuvant chemotherapy (NAC) is currently used for treating breast cancer in selected cases. Our study aims to evaluate the role of automated breast ultrasound (ABUS) in the assessment of response to NAC and compare the ABUS results with MRI. A total of 52 consecutive patients were included in this study.
View Article and Find Full Text PDFJ Breast Imaging
September 2024
RUSH Cancer Center, Chicago, IL, USA.
Objective: To assess features of automated breast US (ABUS) use in women with dense breasts. The number of additional cancers found by ABUS not detected by mammography was also determined.
Methods: This study was approved by the IRB and is HIPAA compliant.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!